NCT06709417View on ClinicalTrials.gov

A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG

Sintilimab

Sintilimab 200mg iv Q3W

DRUG

Chemotherapy

Liposomal paclitaxel: 150mg/m2, Q3W + cisplatin: 75mg/m2, Q3W (combined with PD-1 therapy) Liposomal paclitaxel: 50mg/m2, Q3W + cisplatin: 20mg/m2, Q3W (combined with radiotherapy )

RADIATION

radiotherapy

The total dose is 5040cCy in 28 fractions (5 days per week, 1.8 Gy/day).

Trial Locations (1)

200030

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Chest Hospital

OTHER